Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

被引：0
|
作者：
Binghe Xu
Zefei Jiang
Zhimin Shao
Jiayu Wang
Jifeng Feng
Shuping Song
Zhendong Chen
Kangsheng Gu
Shiying Yu
Yiping Zhang
Chuan Wang
Fengchun Zhang
Junlan Yang
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Medical Oncology, Cancer Hospital and Institute
[2] Beijing 307 Hospital,Cancer Hospital and Shanghai Cancer Institute
[3] Fudan University,First Affiliated Hospital
[4] Jiangsu Cancer Hospital,Tongji Hospital
[5] Shandong Cancer Hospital,Affiliated Union Hospital
[6] Anhui Medical University,Renji Hospital
[7] Huizhong Science and Technique University,undefined
[8] Zhejiang Cancer Hospital,undefined
[9] Fujian Medical University,undefined
[10] Shanghai Jiaotong University,undefined
[11] 301 Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Advanced breast cancer; Anastrozole; Arimidex; China; Faslodex; Fulvestrant; Oestrogen receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 230
页数：7
相关论文
共 50 条
  • [31] CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, A.
    Jerusalem, G.
    Petruzelka, L.
    Torres, R.
    Bondarenko, I
    Khasanov, R.
    Verhoeven, D.
    Pedrini, J.
    Lichinitser, M.
    Pendergrass, K.
    Garnett, S.
    Lindemann, J. P. O.
    Sapunar, F.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 491S - 491S
  • [32] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    Wells, Samuel A., Jr.
    Robinson, Bruce G.
    Gagel, Robert F.
    Dralle, Henning
    Fagin, James A.
    Santoro, Massimo
    Baudin, Eric
    Elisei, Rossella
    Jarzab, Barbara
    Vasselli, James R.
    Read, Jessica
    Langmuir, Peter
    Ryan, Anderson J.
    Schlumberger, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 134 - 141
  • [33] Vandetanib versus erlotinib in patients with previously treated advanced NSCLC: a randomized, double-blind phase III trial (ZEST)
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S358
  • [34] A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).
    Coombes, R. C.
    Von Minckwitz, G.
    Hicks, J.
    Klare, P.
    Evans, A. A.
    Schmidt, M.
    Makris, A.
    Grieve, R.
    Loibl, S.
    Maher, L.
    Mousa, K.
    Buchsenscuhtz, K.
    A'Hern, R.
    Bliss, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Itopride in functional dyspepsia:: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials
    Talley, N. J.
    Tack, J.
    Ptak, T.
    Gupta, R.
    Giguere, M.
    GUT, 2008, 57 (06) : 740 - 746
  • [36] Multicentre, double-blind, randomised placebo-controlled clinical trial on the effi cacy of methylphenidate on depressive symptoms in advanced cancer patients
    Centeno, Carlos
    Sanz, Alvaro
    Angel Cuervo, Miguel
    Ramos, Daniel
    Hernansanz, Silvia
    Gonzalez, Jesus
    Jose Almaraz, Maria
    Lama, Marcos
    Vara, Francisco
    Nabal, Maria
    Pascual, Antonio
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2012, 2 (04) : 328 - 333
  • [37] A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226
    Mehta, Rita S.
    Barlow, William E.
    Albain, Kathy S.
    Vandenberg, Ted A.
    Dakhil, Shakher R.
    Tirumali, Nagendra L.
    Lew, Danika L.
    Hayes, Daniel F.
    Gralow, Julie R.
    Linden, Hannah M.
    Livingston, Robert B.
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2018, 78 (04)
  • [38] Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Zhang, Pin
    Zhang, Qingyuan
    Tong, Zhongsheng
    Sun, Tao
    Li, Wei
    Ouyang, Quchang
    Hu, Xichun
    Cheng, Ying
    Yan, Min
    Pan, Yueyin
    Teng, Yuee
    Yan, Xi
    Wang, Ying
    Xie, Weimin
    Zeng, Xiaohua
    Wang, Xiaojia
    Hu, Changlu
    Geng, Cuizhi
    Zhang, Hongwei
    Li, Wenxin
    Wu, Xinhong
    Zhong, Jincai
    Xu, Jingwei
    Shi, Yanxia
    Wei, Wenhua
    Bayaxi, Nayima
    Zhu, Xiaoyu
    Xu, Binghe
    LANCET ONCOLOGY, 2023, 24 (06): : 646 - 657
  • [39] Anastrozole ('arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind crossover SAKK Trial 21/95 - a sub-study of Anastrozole Trial 0027.
    Thuerlimann, B
    Hess, D
    Koeberle, D
    Senn, I
    Ballabeni, P
    Pagani, O
    Perey, L
    Aebi, S
    Rochlitz, C
    Goldhirsch, A
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S73 - S73
  • [40] Micronised fenofibrate or gemfibrozil in patients with combined hyperlipidaemia: A double-blind randomised multicentre trial
    Dzavik, V
    Ansquer, JC
    Delaval, D
    ATHEROSCLEROSIS, 1999, 144 : 32 - 32
12345